Forx Therapeutics AG presented a comprehensive preclinical medicinal chemistry and translational profiling program describing the optimization of potent and selective poly(ADP-ribose) glycohydrolase inhibitors, which led to the identification of FORX-428, currently in phase I clinical trials. The company also disclosed the chemical structure of the compound.